AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Annovis Bio Inc. (ANVS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.23

-0.08 (-3.46%)

At close: Feb 20, 2025, 3:59 PM

2.23

0.22%

After-hours: Feb 20, 2025, 07:00 PM EST

undefined% (undefined)

Bid	2.21
Market Cap	43.36M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.22
PE Ratio (ttm)	-0.53
Forward PE	n/a
Analyst	Buy

Ask	2.32
Volume	431,939
Avg. Volume (20D)	488,210
Open	2.33
Previous Close	2.31
Day's Range	2.08 - 2.40
52-Week Range	2.09 - 20.00
Beta	undefined

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for prote...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 29, 2020

Employees 6

Stock Exchange NYSE

Ticker Symbol ANVS

Website https://www.annovisbio.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for ANVS stock is "Buy." The 12-month stock price forecast is $25.5, which is an increase of 1046.07% from the latest price.

Buy 71.43%

Hold 14.29%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago

-6.8%

Annovis Bio shares are trading lower after D. Bora... Unlock content with Pro Subscription

2 weeks ago

-33.47%

Annovis Bio shares are trading lower after the company announced a $21 million public offering.

News

7 months ago · zacks.com

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

7 months ago · investorplace.com

Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?

Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap ...

7 months ago · marketwatch.com

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.

8 months ago · zacks.com

Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana...

9 months ago · businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's po...

9 months ago · businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio, Inc....

9 months ago · businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) on behalf of investors concerning the Company's...

9 months ago · seekingalpha.com

Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box

Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.

9 months ago · reuters.com

Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial

Annovis Bio said on Monday that its Alzheimer's treatment showed significantly higher improvement in cognition in Alzheimer's patients during a mid-stage trial.

10 months ago · zacks.com

Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy...

Load More News